Discover GSK in India

In India, GSK has a head office in Mumbai with a manufacturing facility at Nashik in Maharashtra, 20 Contract Manufacturing Organisations (CMOs), regional and sales hubs across India.

GlaxoSmithKline Pharmaceuticals Limited head office, Mumbai

For decades, the centre of our corporate operations has been in the Worli area of Mumbai.

(Dr. Annie Besant Road, Mumbai 400030, Maharashtra, India)

GSK India Head Office, Mumbai

Nashik Manufacturing Unit

The company has made substantial investments in a large manufacturing facility at Nashik, in the state of Maharashtra.

Inaugurated in 1983, the Nashik factory is situated on 47 acres of land in Ambad industrial belt (A-10, Ambad - Uttam Nagar Rd, MIDC Area, MIDC Ambad, Nashik, Maharashtra 422010, India).

The facility manufactures tablets, creams and ointments.

A state of the art manufacturing facility for Eltroxin is now operational at the site. Also, all the existing facilities are regularly upgraded and maintained by developing indigenous technology/solutions & automating operations, to ensure continuous improvements on productivity and efficiency.

GSK India Manufacturing Unit, Nashik

Warehousing and distribution

Our warehousing and distribution network comprising of more than 30 contract manufacturing facilities, 26 warehouses and 6,000 stockists providing high levels of customer service on time.

Global Capability Center, Bengaluru

As part of an inclusive culture, the Global Capacity Center at Bengaluru contributes to a high-performing team to deliver real impact. The Center provides the space and support for people to do their best work. Fewer desks, plants, sound scaping, a wellness centre, air quality displays, and even ambient scents maximise productivity and well-being at the Center.

Watch Video

Key trends in the Indian pharma industry

The government and regulatory landscape

The government and regulatory landscape

  • Healthcare at the centre of the government agenda.
  • Enhanced vigilance on quality from regulators.
  • Faster regulatory approvals for key therapy areas.

Shifting industry dynamics

Shifting industry dynamics

  • Transitioning from 'Make in India' to 'Develop in India'.
  • Rural markets are gaining attention.
  • Greater focus on cost optimisation and cost management

Emergence of new Go-To-Market models

Emergence of new Go-To-Market models

  • Evolution of new channels, along with existing trade channels.
  • Informed patients driving consumerisation.

Digitalisation

Digitalisation

  • Companies are leveraging data and analytics to sharpen their competitive edge.
  • Digitalisation fuelling transformation.